Curatis Holding AG stock analysis
Curatis Holding AG (0QNS) Share Price & Analysis
0QNS Stock Chart & Stats
- Day’s Range
- CHF 17.45 - CHF 17.45
- 52-Week Range
- CHF 11.55 - CHF 25.00
- Previous Close
- CHF 17.45
- Volume
- N/A
- Average Volume (3M)
- 63
- Market Cap
- CHF 85.03M
- Enterprise Value
- CHF 111.64M
- Total Cash (Recent Filing)
- CHF 3.60M
- Total Debt (Recent Filing)
- CHF 0
- Price to Earnings (P/E)
- ―
- Beta
- -0.38
- Next Earnings
- Apr 12, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery
The sharp 2025 revenue rebound indicates improving commercial traction and renewed demand for the company’s pharmaceutical and healthcare activities. If maintained, stronger sales can provide operating leverage, support investment in the portfolio, and improve the foundation for future profitability.
Gross Margin Improvement
Improving gross margin shows that the revenue recovery is accompanied by better economics at the gross-profit level, not just higher sales. Sustained margin expansion would increase the portion of revenue available to cover operating costs and could accelerate the path toward break-even.
Debt-free Balance Sheet
Zero reported debt and a sizeable equity base provide financial flexibility and reduce exposure to interest costs or refinancing pressure. This gives Curatis more capacity to support operations and pursue development while limiting the balance-sheet strain typically associated with leveraged growth.
Bears Say
Persistent Unprofitability
Despite substantial improvement from 2024, the company has not yet reached sustainable profitability across EBIT, EBITDA, or net income. Continued losses can restrict internally funded growth, keep management focused on recovery, and make the improved revenue trend less durable until operating costs are covered.
Worsening Cash Burn
Negative operating and free cash flow show that the business is not yet self-funding, even as reported losses narrow. Worsening cash generation can create continuing funding needs, reduce flexibility for development activities, and weaken the quality of the company’s financial recovery.
Negative Returns On Equity
Negative return on equity indicates that the sizeable capital base is still not generating positive earnings for shareholders. Until returns improve, Curatis may struggle to compound its equity efficiently, while ongoing losses could diminish the strategic benefit of its otherwise strong balance-sheet position.
Curatis Holding AG News
0QNS FAQ
What was Curatis Holding AG’s price range in the past 12 months?
What is Curatis Holding AG’s market cap?
When is Curatis Holding AG’s upcoming earnings report date?
How were Curatis Holding AG’s earnings last quarter?
Is Curatis Holding AG overvalued?
Does Curatis Holding AG pay dividends?
What is Curatis Holding AG’s EPS estimate?
How many shares outstanding does Curatis Holding AG have?
What happened to Curatis Holding AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Curatis Holding AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Curatis Holding AG
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Roland Rutschmann
- Employees
- 9
- Website
- curatis.com
- Address
- Weierweg 7, Liestal, BL, 4410, CH
Curatis Holding AG (0QNS) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 12 |
| Technical Analysis | 3 | 2 | 2 |
| Moving Averages | 1 | 1 | 10 |




